SCHEMBL4019835

SCHEMBL4019835

Cc1ccc(C(=O)NC2CCN(c3ccnc4cc(Cl)ccc34)CC2)cc1.O=C(NC1CCN(c2ccnc3cc(Cl)ccc23)CC1)c1ccc(F)c(F)c1F

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPK1 P28482 4/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 1/20 0.48
STAT3 P40763 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
IDE P14735 3/20 0.48
CLK1 P49759 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024048 0.92 ALDH1A1 (0.56) RXFP1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4024500 0.90 RXFP1 (0.59) RXFP1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4018088 0.85 ALDH1A1 (0.54) MEN1KMT2AMAPK1ALDH1A1MAPT
SCHEMBL4581795 0.85 MAPK1 (0.58) RXFP1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4016159 0.84 MAPK1 (0.57) RXFP1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4021694 0.82 CCNE1 (0.57) RXFP1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4016317 0.82 MAPK1 (0.59) MEN1KMT2AMAPK1ALDH1A1MAPT
SCHEMBL4016311 0.82 ALDH1A1 (0.57) RXFP1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL4019375 0.81 ALDH1A1 (0.56) MEN1KMT2AMAPK1ALDH1A1MAPT
SCHEMBL4018148 0.81 MAPK1 (0.60) MEN1KMT2AMAPK1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP claimed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO claimed